VICOPROFEN Drug Patent Profile

When do Vicoprofen patents expire, and what generic alternatives are available?

Vicoprofen is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in VICOPROFEN is hydrocodone bitartrate; ibuprofen. There are twenty-three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the hydrocodone bitartrate; ibuprofen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vicoprofen

A generic version of VICOPROFEN was approved as hydrocodone bitartrate; ibuprofen by ACTAVIS LABS FL INC on December 31^st, 2003.

Summary for VICOPROFEN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	2
Patent Applications:	193
What excipients (inactive ingredients) are in VICOPROFEN?	VICOPROFEN excipients list
DailyMed Link:	VICOPROFEN at DailyMed

Recent Clinical Trials for VICOPROFEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Icahn School of Medicine at Mount Sinai	N/A
Charleston Laboratories, Inc	Phase 1

See all VICOPROFEN clinical trials

Paragraph IV (Patent) Challenges for VICOPROFEN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VICOPROFEN	Tablets	hydrocodone bitartrate; ibuprofen	10 mg/200 mg	020716	1	2006-03-20
VICOPROFEN	Tablets	hydrocodone bitartrate; ibuprofen	2.5 mg/200 mg	020716	1	2006-02-24

US Patents and Regulatory Information for VICOPROFEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VICOPROFEN	hydrocodone bitartrate; ibuprofen	TABLET;ORAL	020716-001	Sep 23, 1997		DISCN	Yes	No

Expired US Patents for VICOPROFEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	VICOPROFEN	hydrocodone bitartrate; ibuprofen	TABLET;ORAL	020716-001	Sep 23, 1997
Abbvie	VICOPROFEN	hydrocodone bitartrate; ibuprofen	TABLET;ORAL	020716-001	Sep 23, 1997
Abbvie	VICOPROFEN	hydrocodone bitartrate; ibuprofen	TABLET;ORAL	020716-001	Sep 23, 1997

International Patents for VICOPROFEN

See the table below for patents covering VICOPROFEN around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1267847	COMPOSES PHARMACEUTIQUES D'HYDROCODONE/IBUPROFEN ET METHODE (HYDROCODONE/IBUPROFEN PHARMACEUTICAL COMPOSITIONS AND METHOD)
Japan	S61197517	DRUG COMPOSITION
European Patent Office	0186241

VICOPROFEN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Vicoprofen

Introduction to Vicoprofen

Vicoprofen, a brand-name drug, is a combination of hydrocodone, an opioid, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID). It is primarily used as a short-term solution for managing severe pain, particularly in cases where other treatments have been ineffective[5].

Market Size and Growth of Opioids

The global opioids market, within which Vicoprofen operates, was valued at USD 5.4 billion in 2022 and is projected to grow at a CAGR of 3.7% from 2023 to 2032, reaching USD 7.7 billion by 2032. This growth is driven by the increasing approval of opioid medications for treating severe pain caused by chronic diseases[1].

Product Segment Analysis

In the opioids market, the product type segment includes methadone, codeine, fentanyl, oxycodone, morphine, hydrocodone, and others. Hydrocodone, a key component of Vicoprofen, is one of the most commonly prescribed opioid analgesics. Hydrocodone combination products (HCPs) account for a significant portion of the total US opioid sales, with prescriptions increasing from 124.1 million in 2008 to 136.7 million between 2008-2013[2].

Application Segment Analysis

The application segment of the opioids market is dominated by pain management, which accounted for around 39% of the market share in 2022. Vicoprofen, being a pain management drug, benefits from this trend as it is prescribed for severe pain management, including post-surgical pain, cancer pain, and chronic pain conditions[1].

Geographical Analysis

North America, particularly the United States, dominates the opioids market, holding a market share of around 43% in 2022. This region is expected to maintain its dominance due to rising product approvals by regulatory authorities such as the U.S. Food and Drug Administration (FDA). The introduction of new opioid medications and generic forms, like Hikma Pharmaceuticals' Buprenorphine Hydrochloride Injection, further supports market growth in this region[1].

Drivers of Market Growth

Increasing Geriatric Population

The rising geriatric population is a significant driver for the opioids market. As people age, the prevalence of chronic diseases such as cancer, arthritis, and cardiovascular diseases increases, leading to a higher demand for opioid medications to manage chronic pain. The elderly population's growth, driven by declining fertility and death rates, is expected to continue, thereby increasing the demand for drugs like Vicoprofen[1].

Regulatory Approvals

The approval and launch of new opioid medications provide growth opportunities for the market. For instance, the introduction of generic forms of existing opioids can make these medications more accessible and affordable, contributing to market expansion[1].

Restraints on Market Growth

Side Effects and Misuse

One of the major restraints on the opioids market is the associated side effects and the potential for misuse. Opioid drugs, including those containing hydrocodone like Vicoprofen, can lead to addiction and other severe side effects when used without a prescription. This has resulted in significant regulatory scrutiny and public health concerns, which can hamper market growth[1].

Competitive Dynamics

The opioids market is subject to competitive dynamics influenced by federal and state policies. For example, the upscheduling of hydrocodone combination products in 2014 affected the competitive landscape by restricting supply and potentially driving users towards other opioid products or illicit markets. This kind of policy change can impact the sales and market share of drugs like Vicoprofen[2].

Financial Trajectory

Given the overall growth of the opioids market, Vicoprofen is likely to benefit from the increasing demand for pain management solutions. Here are some key financial insights:

• Revenue Potential: As part of the broader opioids market, Vicoprofen's revenue is expected to grow in line with the market's CAGR of 3.7% from 2023 to 2032.
• Market Share: While specific financial data for Vicoprofen is not provided, its position within the hydrocodone segment, which is a significant part of the opioids market, suggests it will continue to generate substantial revenue.
• Cost and Pricing: The cost of Vicoprofen, like other opioid medications, can be influenced by regulatory policies and market competition. For instance, the introduction of generic forms can reduce costs and make the drug more accessible, potentially increasing its market share[1][4].

Industry Trends and Future Outlook

Regulatory Environment

The regulatory environment plays a crucial role in the opioids market. Policies aimed at reducing opioid misuse can impact the sales of drugs like Vicoprofen. However, these policies also drive the development of safer and more controlled opioid formulations, which can present opportunities for growth[2].

Technological Advancements

Advancements in drug delivery systems and the development of abuse-deterrent formulations are expected to shape the future of the opioids market. These innovations could enhance the safety profile of Vicoprofen and other opioid medications, potentially increasing their adoption[1].

Key Takeaways

• Market Growth: The global opioids market, including Vicoprofen, is expected to grow at a CAGR of 3.7% from 2023 to 2032.
• Drivers: Increasing geriatric population and regulatory approvals are key drivers of market growth.
• Restraints: Side effects and misuse of opioid drugs are significant restraints.
• Geographical Dominance: North America, particularly the United States, dominates the market.
• Financial Trajectory: Vicoprofen's revenue is expected to grow in line with the broader opioids market.

FAQs

1. What is Vicoprofen used for? Vicoprofen is used as a short-term solution for managing severe pain, combining hydrocodone and ibuprofen.

2. How does the increasing geriatric population impact the opioids market? The increasing geriatric population drives up the demand for opioid medications due to the higher prevalence of chronic diseases and severe pain among the elderly.

3. What are the main restraints on the opioids market? The main restraints include side effects associated with opioid use and the potential for misuse, which can lead to addiction and other health issues.

4. How does regulatory policy impact the opioids market? Regulatory policies, such as the upscheduling of hydrocodone combination products, can restrict supply and influence the competitive dynamics of the market.

5. What is the projected market size of the opioids market by 2032? The global opioids market is projected to reach USD 7.7 billion by 2032, growing at a CAGR of 3.7% from 2023 to 2032.

Sources

1. The Brainy Insights - Opioids Market Size, Share | CAGR of 3.7% - The Brainy Insights
2. National Bureau of Economic Research - Competitive Effects of Federal and State Opioid Restrictions
3. United Nations Office on Drugs and Crime - DRUG MARKET TRENDS: CANNABIS OPIOIDS
4. U.S. Government Accountability Office - Brand-Name Prescription Drug Pricing
5. Opiates.com - Vicoprofen | Hydrocodone-Based Drug | Waismann Method®